ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
November 01 2023 - 8:34AM
Business Wire
Tru Niagen® Pro 1,000mg is recommended
by physicians and used by pro-athletes as it is clinically proven
to boost NAD+ levels by up to 150% in as little as three weeks
ChromaDex Corp. (NASDAQ:CDXC), a global authority on
Nicotinamide Adenine Dinucleotide (NAD+) research and healthy
aging, launches its clinical strength Tru Niagen® Pro
1,000mg, featuring 1,000mg of Niagen® (patented
Nicotinamide Riboside or NR), one of the most efficient and
superior quality NAD+ precursors on the market, to consumers
nationwide. With 1,000mg of Niagen used in over 50% of published
clinical studies, this serving is redefining research for NAD+
related health outcomes.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231101126568/en/
Clinical strength Tru Niagen Pro 1,000mg,
proven to elevate NAD+ levels up to 150% in as little as three
weeks (Photo: Business Wire)
The most potent serving size of Niagen available for more
pronounced healthy aging benefits, Tru Niagen Pro 1,000mg is
recommended by physicians and used by pro-athletes as it is
clinically proven to elevate NAD+ levels up to 150% in as little as
three weeks. Tru Niagen Pro 1,000mg is Certified for Sport®
by NSF International, which is the only third-party certification
program recognized by the United States Anti-Doping Agency (USADA),
Major League Baseball (MLB), and the National Hockey League
(NHL).
“On behalf of the ChromaDex family, we are proud to bring the
clinical-strength benefits of our profound NAD+ boosting Tru Niagen
to individuals across the nation,” comments Rob Fried, CEO of
ChromaDex. “As a pioneer of NAD+ research, our team works with
esteemed investigators across the globe to uncover the full
potential of NAD+. When using 1,000mg or more of Tru Niagen,
researchers have discovered pronounced benefits in numerous
age-related conditions.”
Dr. Andrew Shao, Senior Vice President of Global Regulatory
& Scientific Affairs, comments, “Research indicates that NAD+
decreases with age and, more specifically, that NAD+ levels are
depressed in organs facing metabolic stress and age-related
functional decline. 1,000mg is the most well-researched daily
Niagen serving in published human studies, the results of which
consistently demonstrate that elevated NAD+ levels correspond to a
range of healthy aging benefits, including lowering age-related
inflammation.”
As ChromaDex holds scientific rigor and quality to the highest
standards, Tru Niagen is backed by two Nobel Prize winners, 25+
human clinical studies, 300 published scientific studies, has been
accepted by the world’s most rigorous regulatory bodies and
undergoes extensive quality testing for potency, safety and purity.
Additionally, published clinical studies indicate that Niagen is
safe to take up to 2,000mg per day.
Tru Niagen Pro 1,000mg was unveiled to a select group of Key
Opinion Leaders (KOLs), physicians, influencers and celebrities at
the Tru Niagen Wellness Retreat in Malibu last week. Guests learned
about the health-altering power of Tru Niagen and NAD+ from a panel
of leading experts including Dr. Aimee, OBGYN and Founder of
The Egg Whisperer, Dr. Darshan Shah, Founder of Next Health,
Dr. Abe Malkin, Founder of Drip Hydration, Brooke
Burke, Founder of Brooke Burke Body and Tru Niagen partner,
Jennifer Cohen, Host of Habits & Hustle Podcast and Tru
Niagen partner, Todd Anderson, Human Performance Coach and
Owner of Dream Recovery, and Mona Rosene, MS, RD, Global
Director of Scientific Affairs at ChromaDex & Tru Niagen.
Tru Niagen Pro 1,000mg retails for $109.99 as a one-time
purchase or $98.99 with a subscription at www.truniagen.com and
will be available for $109.99 at www.amazon.com.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to NR being the most
efficient and superior NAD+ precursor on the market and whether the
1,000mg of Niagen will redefine research for NAD+ related health
outcomes. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101126568/en/
ChromaDex Media Contact: Kendall Knysch, Head of Media
Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com ChromaDex Investor Relations
Contact: +1 (949) 356-1620 InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024